Retrospective study on the efficacy and safety of Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400092471

Enrollment

Unknown

Registered

2024-11-18

Start date

2024-11-20

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult relapsed/refractory FLT3-mutated acute myeloid leukaemia

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily signed informed consent; 2.age >=18; 3.physical condition score 0-2 (ECOG score); 4.all patients underwent at least two or more bone marrow evaluations, including the initial visit, the 28th day after the end of gilteritinib-based combination therapy, and/or the late phase of treatment;

Exclusion criteria

Exclusion criteria: 1.Patients who were deemed by the investigator to be ineligible for participation in the study;

Design outcomes

Primary

Measure	Time frame
CRc;	—

Secondary

Measure	Time frame
minimal residual disease, MRD;Overall survival, OS; Event free survival, EFS; Duration of relief, DOR;Adverse event incidence rate;	—

Countries

China

Contacts

Public ContactShi Pengcheng

Southern Medical University Southern Hospital

shpch283@163.com+86 13632317830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026